Jon Hanifin - Academia.edu (original) (raw)
Papers by Jon Hanifin
British Journal of Dermatology, 2007
Background The safety of topical therapies for atopic dermatitis (AD), a common and morbid diseas... more Background The safety of topical therapies for atopic dermatitis (AD), a common and morbid disease, has recently been the focus of increased scrutiny, adding confusion as how best to manage these patients. Objectives The objective of these systematic reviews was to determine the safety of topical therapies for AD. Methods Databases searched included: OVID Medline, Medline In-Process and Other Non-Indexed Citations, Embase, and the Cochrane Central Register of Controlled Trials. In addition to the articles identified by this search, investigators were also referred to a list of links (most recently updated 25 September 2005) to recent Food and Drug Administration (FDA) studies, reports and meetings regarding the topical calcineurin inhibitors for further potential references. Only fully published papers available in English and data obtained from FDA sites were included. Furthermore, the criteria for inclusion and exclusion for each systematic review were further evaluated at a meeting of all of the content and evidencebased medicine experts participating in this process and alteration of the inclusion criteria was done at that time when it was felt necessary to avoid inclusion of lower-quality data in the review. Qualitative review of the abstracted data was performed and reviewed at a meeting of all of the content and evidencebased medicine experts. Results While systemic exposure to these topical agents does occur, physiological changes appear to be uncommon and systemic complications rare and have only been found with use of topical corticosteroids. Conclusions Based on the data that are available the overall safety of AD therapies appears to be good with the only documented systemic side-effects of therapy those occasionally seen with use of topical corticosteroids. Atopic dermatitis (AD) is an extremely common disease that adversely impacts the quality of life (QoL) of affected children and adults. 1,2 The pathogenesis of AD is incompletely understood, but involves dysregulation of inflammation and the response to antigens. 1,3 Modern therapy of AD has largely been focused on agents that control perturbations in the inflamma-tory response, i.e. anti-inflammatory and immunosuppressive compounds. The spectrum of topical therapies used to treat AD ranges from emollients to potent anti-inflammatory and immunomodulating agents including topical corticosteroids (TS), a class of compounds with a broad effect on immune regulatory functions, and topical calcineurin inhibitors (TCI), more
Journal of the American Academy of Dermatology, 2014
Atopic dermatitis is a common and chronic, pruritic inflammatory skin condition that can affect a... more Atopic dermatitis is a common and chronic, pruritic inflammatory skin condition that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this second of 4 sections, treatment of atopic dermatitis with nonpharmacologic interventions and pharmacologic topical therapies are reviewed. Where possible, suggestions on dosing and monitoring are given based on available evidence. ( J Am Acad Dermatol http://dx.
British Journal of Dermatology, 2007
Background The safety of topical therapies for atopic dermatitis (AD), a common and morbid diseas... more Background The safety of topical therapies for atopic dermatitis (AD), a common and morbid disease, has recently been the focus of increased scrutiny, adding confusion as how best to manage these patients. Objectives The objective of these systematic reviews was to determine the safety of topical therapies for AD. Methods Databases searched included: OVID Medline, Medline In-Process and Other Non-Indexed Citations, Embase, and the Cochrane Central Register of Controlled Trials. In addition to the articles identified by this search, investigators were also referred to a list of links (most recently updated 25 September 2005) to recent Food and Drug Administration (FDA) studies, reports and meetings regarding the topical calcineurin inhibitors for further potential references. Only fully published papers available in English and data obtained from FDA sites were included. Furthermore, the criteria for inclusion and exclusion for each systematic review were further evaluated at a meeting of all of the content and evidencebased medicine experts participating in this process and alteration of the inclusion criteria was done at that time when it was felt necessary to avoid inclusion of lower-quality data in the review. Qualitative review of the abstracted data was performed and reviewed at a meeting of all of the content and evidencebased medicine experts. Results While systemic exposure to these topical agents does occur, physiological changes appear to be uncommon and systemic complications rare and have only been found with use of topical corticosteroids. Conclusions Based on the data that are available the overall safety of AD therapies appears to be good with the only documented systemic side-effects of therapy those occasionally seen with use of topical corticosteroids. Atopic dermatitis (AD) is an extremely common disease that adversely impacts the quality of life (QoL) of affected children and adults. 1,2 The pathogenesis of AD is incompletely understood, but involves dysregulation of inflammation and the response to antigens. 1,3 Modern therapy of AD has largely been focused on agents that control perturbations in the inflamma-tory response, i.e. anti-inflammatory and immunosuppressive compounds. The spectrum of topical therapies used to treat AD ranges from emollients to potent anti-inflammatory and immunomodulating agents including topical corticosteroids (TS), a class of compounds with a broad effect on immune regulatory functions, and topical calcineurin inhibitors (TCI), more
Journal of the American Academy of Dermatology, 2014
Atopic dermatitis is a common and chronic, pruritic inflammatory skin condition that can affect a... more Atopic dermatitis is a common and chronic, pruritic inflammatory skin condition that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this second of 4 sections, treatment of atopic dermatitis with nonpharmacologic interventions and pharmacologic topical therapies are reviewed. Where possible, suggestions on dosing and monitoring are given based on available evidence. ( J Am Acad Dermatol http://dx.